



Our Mission: Targeting Coenzyme-A for PKAN

April 2021 | Non-Confidential

In memory of Riley, pictured
2008–2019



Disclaimers & Reminders

The information included here is not meant for use in any other setting and is intended to serve as talking points for discussion with patient advocacy organizations.

BBP-671 is an investigational drug. The safety and efficacy of BBP-671 have not been established. There is no guarantee that BBP-671 will receive health authority approval or become commercially available in any country in which it is being investigated.

BridgeBio Pharma: Hope Through Rigorous Science

Our Mission: To **discover**, **create**, **test**, and **deliver** transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers



*In memory of Riley, pictured
2008–2019*

Our Values

put patients first

think independently

be radically transparent

every minute counts


let science speak

CoA Therapeutics is an affiliate of BridgeBio Pharma



Snapshot

- Founded in 2015
- Portfolio of ~20 affiliate companies, each focused on developing one molecule
- Focus on inherited disorders and genetically-driven cancers
- Targeting diseases at their source




At CoA Therapeutics, we are developing BBP-671 as a potential treatment for PKAN


Pantothenate kinase associated neurodegeneration (PKAN) is caused by mutations in **PANK2**, resulting in **decreased CoA**, and leading to neurodegeneration

BBP-671 is a pantazine and acts by activating **PanK1 and PanK3**

- BBP-671 is intended to compensate for the loss of PanK2 activity to increase CoA in the brain




In a mouse model of PKAN, CoA Therapeutics' pantazines improve **movement** and **survival**



- Impaired movement was observed in a mouse model of PKAN
- Pantazines improved movement in a mouse model of PKAN

We are currently investigating BBP-671 in a Phase 1 study in healthy volunteers

- We are currently studying BBP-671 in healthy individuals in a Phase 1 study to assess the drug's safety
- We hope to start a PKAN clinical trial in 2022 after learning about BBP-671 drug properties and safety in healthy volunteers
- The US FDA has granted BBP-671 orphan drug designation and rare pediatric drug designation for PKAN



- If you would like further information, please visit our website: <https://coatherapeutics.com/>
- If you have any questions, please do not hesitate to contact us at info@coatherapeutics.com

Note: * Start date depends on completion of Phase 1 study

Collaboration is Critical For Our Success

Your insights and feedback will inform our decisions and actions

